Stock OXMDGG MEDIGENE NA
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Other languages MEDIGENE NA Swiss Exchange

Equities

OXMDGG

DE0005020903

End-of-day quote Swiss Exchange
Other stock markets
- EUR - Intraday chart for MEDIGENE NA
05-21 Medigene, BioNTech Extend Cancer Immunotherapy Partnership MT
05-21 Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Medigene AG Expands its End-to-End Platform by Submitting Three Development Optimization Technology Patents to the European Patent Office
Medigene, BioNTech Extend Cancer Immunotherapy Partnership
Medigene's Global Research & Collaboration Agreement with BioNTech to Extend Beyond Initially Announced Term
Medigene AG's Global Research & Collaboration Agreement with BioNTech SE to Extend Beyond Initial Announced Term
Medigene : Description of the remuneration system for Supervisory Board members
Medigene : Report of the Executive Board on agenda item 8
Medigene : Report of the Executive Board on agenda item 9
Medigene : Explanations of the rights of shareholders
Medigene : Proxy to third person
Medigene : Data protection information
Medigene : CV Dr. Gerd Zettlmeissl
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
Medigene Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS
Medigene AG Extends Cash Runway into July 2025 After Successful Oversubscribed Capital Raise
Medigene Ag Maintains Earnings Guidance for 2024
Medigene Boosts Share Capital Via Rights Offering, Private Placement
Medigene to Present at Upcoming Conferences
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 targeted T Cell Receptor
Medigene AG Expands Patent Portfolio with European Patent Grant for its NY-ESO-1 – targeted T Cell Receptor
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MDG1 Stock
  4. OXMDGG Stock
  5. News MEDIGENE NA
  6. Other languages